- •PROGRESS IN BRAIN RESEARCH
- •List of Contributors
- •Preface
- •Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects
- •Introduction
- •Prevalence of glaucoma
- •PAC suspect
- •PACG
- •Incidence of glaucoma
- •Blinding effects of glaucoma
- •Abbreviations
- •Acknowledgment
- •References
- •Predictive models to estimate the risk of glaucoma development and progression
- •Risk assessment in ocular hypertension and glaucoma
- •Risk factors for glaucoma development
- •Intraocular pressure
- •Corneal thickness
- •Cup/disc ratio and pattern standard deviation
- •The need for predictive models
- •Predictive models for glaucoma development
- •Predictive models for glaucoma progression
- •Limitations of predictive models
- •References
- •Intraocular pressure and central corneal thickness
- •Main text
- •References
- •Angle-closure: risk factors, diagnosis and treatment
- •Introduction
- •Mechanism
- •Other causes of angle closure
- •Risk factors
- •Age and gender
- •Ethnicity
- •Ocular biometry
- •Genetics
- •Diagnosis
- •Acute primary angle closure
- •Angle assessment in angle closure
- •Gonioscopy technique
- •Ultrasound biomicroscopy (UBM)
- •Scanning peripheral anterior chamber depth analyzer (SPAC)
- •Management
- •Acute primary angle closure
- •Medical therapy
- •Argon laser peripheral iridoplasty (ALPI)
- •Laser peripheral iridotomy (PI)
- •Lens extraction
- •Monitoring for subsequent IOP rise in eyes with APAC
- •Fellow eye of APAC
- •Chronic primary angle-closure glaucoma (CACG)
- •Laser peripheral iridotomy
- •Laser iridoplasty
- •Medical therapy
- •Trabeculectomy
- •Lens extraction
- •Combined lens extraction and trabeculectomy surgery
- •Goniosynechialysis
- •Summary
- •List of abbreviations
- •References
- •Early diagnosis in glaucoma
- •Introduction
- •History and examination
- •Quantitative tests and the diagnostic process
- •Pretest probability
- •Test validity
- •Diagnostic test performance
- •Posttest probability
- •Combing test results
- •Selective tests of visual function
- •Early glaucoma diagnosis from quantitative test results
- •Progression to make a diagnosis
- •Conclusions
- •Abbreviations
- •References
- •Monitoring glaucoma progression
- •Introduction
- •Monitoring structural damage progression
- •Monitoring functional damage progression
- •Abbreviations
- •References
- •Standard automated perimetry and algorithms for monitoring glaucoma progression
- •Standard automated perimetry
- •Global indices
- •HFA: MD, SF, PSD, CPSD
- •Octopus indices: MD, SF, CLV
- •OCTOPUS seven-in-one report (Fig. 2)
- •SAP VF assessment: full-threshold strategy
- •SAP VF defects assessment: OHTS criteria
- •SAP VF defects assessment: AGIS criteria
- •SAP VF defects assessment: CIGTS
- •Fastpac
- •Swedish interactive threshold algorithm
- •SAP VF assessment: the glaucoma staging system
- •SAP: interocular asymmetries in OHTS
- •SAP, VF progression
- •SAP: the relationship to other functional and structural diagnostic tests in glaucoma
- •SAP, FDP-Matrix
- •SAP, SWAP, HPRP, FDT
- •SAP: the relationship between function and structure
- •SAP, confocal scanning laser ophthalmoscopy, SLP-VCC
- •SAP, optical coherence tomography
- •SAP and functional magnetic resonance imaging
- •References
- •Introduction
- •Retinal ganglion cells: anatomy and function
- •Is glaucoma damage selective for any subgroup of RGCs?
- •Segregation
- •Isolation
- •FDT: rationale and perimetric techniques
- •SWAP: rationale and perimetric techniques
- •FDT: clinical data
- •SWAP: clinical data
- •Clinical data comparing FDT and SWAP
- •Conclusions
- •References
- •Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma
- •The GDx scanning laser polarimeter
- •Serial analysis
- •Limits
- •The Heidelberg retinal tomograph
- •Limits
- •Conclusions
- •References
- •The role of OCT in glaucoma management
- •Introduction
- •How OCT works
- •How OCT is performed
- •Evaluation of RNFL thickness
- •Evaluation of optic disc
- •OCT in glaucoma management
- •New perspective
- •Abbreviations
- •References
- •Introduction
- •Technology
- •Visual stimulation
- •Reproducibility and habituation of RFonh
- •Retinal neural activity as assessed from the electroretinogram (ERG)
- •The Parvo (P)- and Magno (M)-cellular pathways
- •Physiology
- •Magnitude and time course of RFonh in humans
- •Varying the parameters of the stimulus on RFonh
- •Luminance versus chromatic modulation
- •Frequency
- •Effect of pattern stimulation
- •Neurovascular coupling in humans
- •Clinical application
- •RFonh in OHT and glaucoma patients
- •Discussion
- •FLDF and neurovascular coupling in humans
- •Comments on clinical application of FLDF in glaucoma
- •Conclusions and futures directions
- •Acknowledgements
- •References
- •Advances in neuroimaging of the visual pathways and their use in glaucoma
- •Introduction
- •Conventional MR imaging and the visual pathways
- •Diffusion MR imaging
- •Functional MR imaging
- •Proton MR spectroscopy
- •References
- •Primary open angle glaucoma: an overview on medical therapy
- •Introduction
- •When to treat
- •Whom to treat
- •Genetics
- •Race
- •Ocular and systemic abnormalities
- •Tonometry and pachymetry
- •How to treat
- •Beta-blockers
- •Prostaglandins
- •Alpha-agonists
- •Carbonic anhydrase inhibitors (CAIs)
- •Myotics
- •Fixed combinations
- •References
- •The treatment of normal-tension glaucoma
- •Introduction
- •Epidemiology
- •Clinical features
- •Optic disk
- •Central corneal thickness
- •Disease course
- •Risk factors
- •Intraocular pressure
- •Local vascular factors
- •Immune mechanisms
- •Differential diagnosis
- •Diagnostic evaluation
- •Therapy
- •IOP reduction
- •Systemic medications
- •Neuroprotection
- •Noncompliance
- •Genetics of NTG
- •Abbreviations
- •References
- •The management of exfoliative glaucoma
- •Introduction
- •Epidemiology
- •Ocular and systemic associations
- •Ocular associations
- •Systemic associations
- •Pathogenesis of exfoliation syndrome
- •Mechanisms of glaucoma development
- •Management
- •Medical therapy
- •Laser surgery
- •Operative surgery
- •Future treatment of exfoliation syndrome and exfoliative glaucoma
- •Treatment directed at exfoliation material
- •References
- •Laser therapies for glaucoma: new frontiers
- •Background
- •Laser iridotomy
- •Indications
- •Contraindications
- •Patient preparation
- •Technique
- •Nd:YAG laser iridectomy
- •Argon laser iridectomy
- •Complications
- •LASER trabeculoplasty
- •Treatment technique
- •Mechanism of action
- •Indications for treatment
- •Contraindications to treatment
- •Patient preparation and postoperative follow-up
- •Complications of the treatment
- •Selective laser trabeculoplasty
- •Results
- •LASER iridoplasty
- •Indications
- •Contraindications
- •Treatment technique
- •Complications
- •LASER cyclophotocoagulation
- •Introduction
- •Indications and contraindications
- •Patient preparation
- •Transpupillary cyclophotocoagulation
- •Endoscopic cyclophotocoagulation
- •Transscleral cyclophotocoagulation
- •Transscleral noncontact cyclophotocoagulation
- •Transscleral contact cyclophotocoagulation
- •Complications
- •Excimer laser trabeculotomy
- •References
- •Modulation of wound healing during and after glaucoma surgery
- •The process of wound healing
- •Using surgical and anatomical principles to modify therapy
- •Growth factors
- •Cellular proliferation and vascularization
- •Cell motility, matrix contraction and synthesis
- •Drug delivery
- •Future directions: total scarring control and tissue regeneration
- •Acknowledgments
- •References
- •Surgical alternative to trabeculectomy
- •Introduction
- •Deep sclerectomy
- •Viscocanalostomy
- •Conclusions
- •References
- •Modern aqueous shunt implantation: future challenges
- •Background
- •Current shunts and factors affecting their function
- •Shunt-related factors
- •Surface area
- •Plate material
- •Valved versus non-valved
- •Commercially available devices
- •Comparative studies
- •Patient and ocular factors
- •Severity of glaucoma damage
- •Tolerance of topical ocular hypotensive medications
- •Aqueous hyposecretion
- •Previous ocular surgery
- •Scleral thinning
- •Patient cooperation for and tolerance of potential slit-lamp interventions
- •Future challenges
- •Predictability
- •Cataract formation
- •The long-term effect on the cornea
- •References
- •Model systems for experimental studies: retinal ganglion cells in culture
- •Mixed RGCs in culture
- •Retinal explants
- •Glial cultures
- •RGC-5 cells
- •Differentiation of RGC-5 cells
- •RGC-5 cell neurites
- •Advantages and disadvantages of culture models
- •References
- •Rat models for glaucoma research
- •Rat models for glaucoma research
- •Use of animal models for POAG
- •Suitability of the rat for models of optic nerve damage in POAG
- •Methods for measuring IOP in rats
- •General considerations for measuring IOP in rats
- •Assessing optic nerve and retina damage
- •Experimental methods of producing elevated IOP
- •Laser treatment of limbal tissues
- •Episcleral vein cautery
- •Conclusions
- •Abbreviations
- •Acknowledgements
- •References
- •Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection
- •Introduction
- •The mouse as a model system
- •Mice are suitable models for studying IOP elevation in glaucoma
- •Tools for glaucoma research
- •Accurate IOP measurements are fundamental to the study of glaucoma
- •The future of IOP assessment
- •Assessment of RGC function
- •Mouse models of glaucoma
- •Primary open-angle glaucoma
- •MYOC
- •OPTN
- •Strategies for developing new models of POAG
- •Developmental glaucoma
- •Pigmentary glaucoma
- •Experimentally induced models of glaucoma
- •Mouse models to characterize processes involved in glaucomatous neurodegeneration
- •Similar patterns of glaucomatous damage occur in humans and mice
- •The lamina cribrosa is an important site of early glaucomatous damage
- •An insult occurs to the axons of RGCs within the lamina in glaucoma
- •What is the nature of the insult at the lamina?
- •Other changes occur in the retina in glaucoma
- •PERG and complement
- •Using mouse models to develop neuroprotective strategies
- •Somal protection
- •Axonal protection
- •Erythropoietin administration
- •Radiation-based treatment
- •References
- •Clinical trials in neuroprotection
- •Introduction
- •Methods of clinical studies
- •Issues in the design and conduct of clinical trials
- •Clinical trials of neuroprotection
- •Clinical trials of neuroprotection in ophthalmology
- •Endpoints
- •Neuroprotection and glaucoma
- •Conclusions
- •Abbreviations
- •References
- •Pathogenesis of ganglion ‘‘cell death’’ in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria
- •Introduction
- •Retinal ganglion cells and mitochondria
- •Possible causes for ganglion cell death in glaucoma
- •Mitochondrial functions and apoptosis
- •Mitochondrial function enhancement and the attenuation of ganglion cell death
- •Creatine
- •Nicotinamide
- •Epigallocatechin gallate
- •Conclusion
- •References
- •Astrocytes in glaucomatous optic neuropathy
- •Introduction
- •Quiescent astrocytes
- •Reactive astrocytes in glaucoma
- •Signal transduction in glaucomatous astrocytes
- •Protein tyrosine kinases (PTKs)
- •Serine/threonine protein mitogen-activated kinases (MAPKs)
- •G protein-coupled receptors
- •Ras superfamily of small G proteins
- •Astrocyte migration in the glaucomatous optic nerve head
- •Cell adhesion of ONH astrocytes
- •Connective tissue changes in the glaucomatous optic nerve head
- •Extracellular matrix synthesis by ONH astrocytes
- •Extracellular matrix degradation by reactive astrocytes
- •Oxidative stress in ONH astrocytes
- •Conclusions
- •Acknowledgments
- •References
- •Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation
- •Glaucoma as a neurodegenerative disease
- •Oxidative stress and free radicals
- •Excessive glutamate, increased calcium levels, and excitotoxicity
- •Deprivation of neurotrophins and growth factors
- •Abnormal accumulation of proteins
- •Pharmacological neuroprotection for glaucoma
- •Protection of the retinal ganglion cells involves the immune system
- •Searching for an antigen for potential glaucoma therapy
- •Concluding remarks
- •References
- •Oxidative stress and glaucoma: injury in the anterior segment of the eye
- •Introduction
- •Oxidative stress
- •Trabecular meshwork
- •IOP increase and free radicals
- •Glaucomatous cascade
- •Nitric oxide and endothelins
- •Extracellular matrix
- •Metalloproteinases
- •Other factors of interest
- •Therapeutic and preventive substances of interest in glaucoma
- •Ginkgo biloba extract
- •Green tea
- •Ginseng
- •Memantine and its derivates
- •Conclusions
- •Abbreviations
- •References
- •Conclusions on neuroprotective treatment targets in glaucoma
- •Acknowledgments
- •References
- •Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death
- •Introduction
- •Intrinsic apoptosis vs. extrinsic apoptosis
- •The Bcl2 family of proteins
- •The requirement of BAX for RGC soma death
- •BH3-only proteins and the early signaling of ganglion cell apoptosis
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •Assessment of neuroprotection in the retina with DARC
- •Introduction
- •DARC
- •Introducing the DARC technique
- •Annexin 5-labeled apoptosis and ophthalmoloscopy
- •Detection of RGC apoptosis in glaucoma-related animal models with DARC
- •Assessment of glutamate modulation with DARC
- •Glutamate at synaptic endings
- •Glutamate excitotoxicity in glaucoma
- •Assessment of coenzyme Q10 in glaucoma-related models with DARC
- •Summary
- •Abbreviations
- •Acknowledgment
- •References
- •Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
- •Introduction
- •The endocannabinoid system in the eye
- •The IOP-lowering effects of endocannabinoids
- •Endocannabinoids and neuroprotection
- •Conclusions
- •References
- •Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration
- •Retinal ganglion cells, retino-geniculate neurons
- •Lateral geniculate nucleus
- •Mechanisms of RGC injury in glaucoma
- •Transsynaptic degeneration of the lateral geniculate nucleus in glaucoma
- •Neural degeneration in magno-, parvo-, and koniocellular LGN layers
- •Visual cortex in glaucoma
- •Neuropathology of glaucoma in the visual pathways in the human brain
- •Mechanisms of glaucoma damage in the central visual pathways
- •Implications of central visual system injury in glaucoma
- •Conclusion
- •Acknowledgments
- •References
- •Clinical relevance of optic neuropathy
- •Is there a remodeling of retinal circuitry?
- •Behavioral consequences of glaucoma
- •Glaucoma as a neurodegenerative disease versus neuroplasticity and adaptive changes
- •Future directions
- •Acknowledgment
- •References
- •Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
- •Introduction
- •Channel properties of NMDA receptors correlated with excitotoxicity
- •Downstream signaling cascades after overactivation of NMDA receptors
- •Relevance of excitotoxicity to glaucoma
- •Therapeutic approaches to prevent RGC death by targeting the pathways involved in NMDA excitotoxicity
- •Drugs targeting NMDA receptors
- •Kinetics of NMDA receptor antagonists
- •Memantine
- •NitroMemantines
- •Drugs targeting downstream signaling molecules in NMDA-induced cell death pathways
- •p38 MAPK inhibitors
- •Averting caspase-mediated neurodegeneration
- •Abbreviations
- •Acknowledgments
- •References
- •Stem cells for neuroprotection in glaucoma
- •Introduction
- •Glaucoma as a model of neurodegenerative disease
- •Why use stem cells for neuroprotective therapy?
- •Stem cell sources
- •Neuroprotection by transplanted stem cells
- •Endogenous stem cells
- •Key challenges
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells
- •Introduction
- •Glaucoma and the RGCs
- •Are other retinal cells affected in glaucoma?
- •Retinal ischemia related glaucoma
- •Excitotoxicity and the retina
- •Signal transduction
- •NMDA receptor antagonists and CaMKII
- •Caspase-3 activation in NMDA-induced retinal cell death and its inhibition by m-AIP
- •BDNF and neuroprotection of RGCs
- •Summary and conclusions
- •Abbreviations
- •Acknowledgments
- •References
- •Evidence of the neuroprotective role of citicoline in glaucoma patients
- •Introduction
- •Patients: selection and recruitment criteria
- •Pharmacological treatment protocol
- •Methodology of visual function evaluation: electrophysiological examinations
- •PERG recordings
- •VEP recordings
- •Statistic evaluation of electrophysiological results
- •Electrophysiological (PERG and VEP) responses in OAG patients after the second period of evaluation
- •Effects of citicoline on retinal function in glaucoma patients: neurophysiological implications
- •Effects of citicoline on neural conduction along the visual pathways in glaucoma patients: neurophysiological implications
- •Possibility of neuroprotective role of citicoline in glaucoma patients
- •Conclusive remarks
- •Abbreviations
- •References
- •Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon
- •Neuroprotection: VEGF-A, a shared growth factor
- •VEGF-A isoforms
- •VEGF-A receptors
- •Angiogenesis, mitogenesis, and endothelial survival
- •Neurotrophic and neuroprotective effect
- •Intravitreal VEGF inhibition therapy and neuroretina toxicity
- •Neuroprotection: clusterin, a multifunctional protein
- •Clusterin/ApoJ: a debated physiological role
- •Clusterin and diseases
- •Clusterin and the nervous system
- •Neuroprotection: IL-6, VEGF, clusterin, and glaucoma
- •Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
- •Introduction
- •Ischemia model
- •Neuroprotective effect of Coenzyme Q10 against cell loss yielded by transient ischemia in the RGC layer
- •Retinal ischemia and glutamate
- •Coenzyme Q10 minimizes glutamate increase induced by ischemia/reperfusion
- •Summary
- •Acknowledgment
- •References
- •17beta-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
- •Methods
- •Morphometric analysis
- •Microdialysis
- •Drug application
- •Statistical analysis
- •Results
- •17beta-Estradiol pretreatment minimizes RGC loss
- •Discussion
- •Acknowledgment
layers, called parvocellular layers, receive input from P RGCs conveying red–green color information. The koniocellular neurons located between principal layers receive input from K RGCs conveying blue–yellow color information (Kaplan, 2004). Each LGN layer receives input from one eye only: Layers 2, 3, and 5 receive input from the ipsilateral eye, and layers 1, 4, and 6 from the contralateral eye. Within the LGN, approximately 20% of the LGN neurons are GABAergic interneurons remaining in the LGN (Montero and Zempel, 1986), while 80% are relay neurons with their axons forming optic radiations that convey visual information to the primary visual cortex. Only a minority of synaptic inputs onto geniculate relay cells derive from retina (less than 10%), with the majority of synaptic input coming from GABAergic interneurons, cortical, and subcortical inputs (Van Horn et al., 2000).
Mechanisms of RGC injury in glaucoma
The death or loss of RGCs is accepted as the pathological correlate of irreversible vision loss in glaucoma. The loss of RGCs is slow and partial, and accompanied by a specific visual field loss pattern that extends in a progressive manner. Some evidence suggests that RGC death is apoptotic in nature (Quigley, 1999), and primary mechanisms leading to programmed cell death have been reviewed elsewhere (Weinreb and Khaw, 2004). Our understanding of this process is based on experimental work performed in glaucoma models with elevated IOP and optimized over the years to study the sequence of pathological events triggered by IOP elevation (Morrison et al., 1997; Gabelt et al., 2003; Lindsey and Weinreb, 2005; Weinreb and Lindsey, 2005). These pathological events associated with RGC death include glial cell alteration at the optic nerve head, disruption of intracellular transport mechanisms leading to growth factor deprivation, oxidative stress, glutamate excitotoxicity, immune alterations, and vascular pathology (Weinreb and Khaw, 2004; Nickells, 2007; Feilchenfeld et al., 2008) (Fig. 2). However, careful examination of the retina and optic nerve in these models and human glaucoma indicates that a significant
467
proportion of RGCs are neither dead nor completely healthy and that surviving RGCs show subtle morphological changes including shrinkage of cell body, dendrites, and axons (Weber et al., 1998; Morgan et al., 2000). Morphological changes correlated with altered function (Weber and Harman, 2005), and it is possible that these early changes contribute to visual dysfunction in glaucoma. The relationship between IOP elevation and these changes is not completely elucidated, and there is no clear evidence to suggest that dysfunctional cells are destined to die. Factors implicated in RGC death may also be relevant to early injury and cell changes.
Transsynaptic degeneration of the lateral geniculate nucleus in glaucoma
In several neurodegenerative diseases, central nervous system (CNS) injury spreads from a population of neurons to other neuronal populations along anatomical and functional connections (Saper et al., 1987; Kume et al., 1993; Suzuki et al., 1995; Su et al., 1997). This process, called transsynaptic or transneuronal degeneration, is critical to disease progression in many neurological disorders, such as neurons involved in cognition in Alzheimer’s disease (Su et al., 1997). A striking example of this process is in the visual system where transsynaptic degeneration has been observed in the LGN in humans following removal of the eye, a total deafferentation severing all RGC axons (Goldby, 1957). Systematic studies of this process following unilateral enucleation in nonhuman primates demonstrated atrophy of LGN neurons in all animals (Matthews et al., 1960) and loss of LGN neurons in those with longer survival time (Matthews, 1964).
Studies of transsynaptic degeneration in glaucoma come mainly from the experimental monkey model of glaucoma. In this model, the fluid drainage pathway of the eye, the trabecular meshwork, is lasered excessively by argon laser trabeculoplasty, inducing scarring and restricting fluid exit from the eye (Gaasterland and Kupfer, 1974). This caused IOP elevation, typically induced in one eye, after which eye pressure is monitored in both
468
Fig. 2. Diagram illustrating multiple cell types and mechanisms implicated in neural degeneration in glaucoma.
experimental |
and fellow non-glaucoma eyes |
(Fig. 3). The |
experimental primate model of |
glaucoma is highly relevant to human disease due to similar anatomy and physiology of central visual pathways (Kaplan, 2004); mimicking of characteristic glaucomatous optic nerve changes observed in human glaucoma (Quigley et al., 1981; Yu¨cel et al., 1999; Gabelt et al., 2003) and monkeys trained to perform reliable visual field testing show visual deficits similar to those observed in patients with glaucoma (Harwerth et al., 2002). In addition to IOP, optic disk changes (Yu¨cel et al., 1998; Burgoyne et al., 2002; Hare et al., 2004) and visual electrophysiological changes (Frishman et al., 1996; Hare et al., 1999) can be monitored in vivo. After exposure to elevated IOP, postmortem retina and optic nerve are studied to assess pathological events in these tissues. Chronic elevated IOP in the primate model induces blocked anterograde transport to the LGN and retrograde transport at the level of the lamina cribrosa (Quigley and Anderson, 1976; Gaasterland, 1978; Quigley and Addicks, 1980; Radius and Anderson, 1981a, b), leading to RGC death (Quigley, 1999), and atrophy of
surviving cell bodies and dendrites (Weber et al., 1998; Morgan et al., 2000). Although axon size measurement suggested selective loss of larger neurons (Glovinsky et al., 1991), presumably M RGCs, atrophy of RGC axons (Morgan et al., 2000) was not considered.
In experimental primate glaucoma, varying degrees of RGC loss measured by established histomorphometric techniques can be observed (Fig. 4). This includes no evidence of RGC loss with elevated IOP, or partial loss of RGCs, and even total RGC loss with replacement by glial scar (Yu¨cel et al., 1999).
Glaucomatous RGC loss and atrophy spread by anterograde degeneration to major visual pathways in the brain (Gupta and Yu¨cel, 2003).
Neural degeneration in magno-, parvo-, and koniocellular LGN layers
Following elevated IOP in the monkey eye, metabolic changes have been noted in the LGN layers connected to the glaucomatous eye (Vickers
469
Fig. 3. Laser-induced injury to one eye induces elevated intraocular pressure that can be monitored in the experimental right and fellow non-glaucoma eyes over time.
Fig. 4. Following experimentally induced elevated intraocular pressure in monkey, glaucomatous optic nerves show overall atrophy and varying degree of optic nerve fiber loss compared to the control optic nerve on the right (myelin stain in black). The bar indicates 1 mm. Adapted with permission from Yu¨cel et al. (1999).
470
et al., 1997; Crawford et al., 2000). Loss of magnoand parvocellular relay neurons in this model occurred (Weber et al., 2000; Yu¨cel et al., 2000) and increased with optic nerve fiber loss and mean IOP (Yu¨cel et al., 2003) (Fig. 5). Surviving neurons showed atrophy that also increased with these parameters (Yu¨cel et al., 2001), more pronounced in parvocellular layers (Yu¨cel et al., 2001). The latter was even observed in monkeys with ocular hypertension without detectable optic nerve fiber loss (Yu¨cel et al., 2001). In fact, this group also showed reduced LGN dendrite complexity and field area (Gupta et al., 2007), indicating that not all changes are attributable to deafferentation of the visual system.
In the koniocellular pathway, the alpha subunit of type II calmodulin-dependent protein kinase (CaMK-II alpha), a selective marker for these neurons and a major postsynaptic density protein (Hendry and Reid, 2000), was reduced in primate glaucoma (Yu¨cel et al., 2003). Decreased immunoreactivity was observed also in ocular hypertensive monkeys without evidence of optic nerve fiber loss
(Yu¨cel et al., 2003). This finding suggests that neurochemical alterations at the synaptic level occur at early stages of LGN injury to this blue–yellow pathway. Thus, transsynaptic degeneration of the LGN in primate glaucoma appears to affect the three major vision channels, namely the magno-, parvo-, and koniocellular pathways (Yu¨cel et al., 2003).
While changes to relay neurons in experimental glaucoma are described above, it is not known whether GABAergic interneurons in the LGN are also altered in glaucoma as has been observed following enucleation and monocular deprivation (Hendry, 1991).
Glial cells including astrocytes and NG2 cells also appeared altered in experimental glaucoma involving the optic tract and LGN (Yu¨cel et al., unpublished data). Further studies are needed to characterize the involvement of other cell types such as microglia (Wang et al., 2000), vascular (Luthra et al., 2005), and perivascular cells in the LGN in glaucoma.
Mechanisms related to transsynaptic degeneration in glaucoma may be relevant to strategies
Fig. 5. Cross-sections of the right lateral geniculate nucleus in control (right) and glaucomatous monkeys (left) show six distinct neuronal layers. Compared to the control, in glaucoma, overall atrophy is observed. Parvalbumin stains relay neurons, and immunoreactivity in layers 1, 4, and 6 connected to the glaucomatous right eye is decreased. Adapted with permission from Yu¨cel et al. (2000). Copyright r (2000), American Medical Association.
